Effects of Luseogliflozin on Left Ventricular Diastolic Function in Patients with Type 2 Diabetes and Established Cardiovascular Disease
Not Applicable
- Conditions
- The patients with type 2 diabetes and cardiovascular disease
- Registration Number
- JPRN-UMIN000040442
- Lead Sponsor
- Saiseikai Fukuoka General Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
already taking an SGLT2 inhibitor, age < 30 years or >= 75 years, diagnosis of type 1 diabetes or insulin-dependent diabetes, symptomatic heart failure (NYHA II-IV), severe renal dysfunction (eGFR < 45 mL/min/1.73 m2), severe liver dysfunction (over 3* upper limit of normal), diabetic ketoacidosis or diabetic coma the presence of malignancy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method